Thrombin: Structure, biochemistry, measurement, and status in clinical medicine

Journal of Thrombosis and Thrombolysis

Volumn 5, Issue 3, 1998, Pages 215-229

  Becker, Richard C ^a   Spencer, Frederick A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Acute coronary syndromes; Thrombin

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; CYTOKINE; FIBRIN; FIBRINOGEN; HEPARIN; HIRUDIN; PLASMINOGEN ACTIVATOR; PROTHROMBIN; STREPTOKINASE; THROMBIN; THROMBIN INHIBITOR;

BINDING SITE; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; THROMBOCYTE ACTIVATION;

EID: 0031778563     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008843925851     Document Type: Review

References (73)

1. Mann KG, Lawson JH. The role of the membrane in the expression of the vitamin K-dependent enzymes. Arch Pathol Lab Med 1992;116:1330-1336.
2. Church WR, Boulanger LL, Messier TL, Mann KG. Evidence for a common metal ion-dependent transition in the 4-carboxyglutamic acid domains of several vitamin K dependent proteins. J Biol Chem 1989;264:17882-17887.
3. Malhotra DP, Nesheim ME, Mann KG. The kinetics of activation of normal and gammacarboxyglutamaic acid-deficient prothrombins. J Biol Chem 1985;260:279-287.
4. Mann KG, Krishnaswamy S, Lawson JH. Surface dependent hemostasis. Semin Hematol 1992;29:213-226.
5. Silverberg SA, Nemerson Y, Zur M. Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. J Biol Chem 1977;252:8481-8488.
6. Viskup RW, Tracy PB, Mann KG. The isolation of human platelet factor V. Blood 1987;69:1188-1195.
7. Bloom JW, Neisheim ME, Mann KG. Phospholipid binding properties of bovine factor V and factor Va. Biochemistry 1979;18:4419-4425.
8. Higgins DL, Mann RG. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem 1983;258:6503-6508.
9. Tracy PB, Mann KG. Prothrombinase complex assembly on the platelet surface is mediated through the 74,000 dalton component of factor Va. Proc Natl Acad Sci USA 1983;80: 2380-2384.
10. Esmon CT. The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J Biol Chem 1979; 254:964-973.
11. Nesheim ME, Mann KG Thrombin-catalyzed activation of single chain bovine factor V. J Biol Chem 1979;254: 1326-1334.
12. Foster WB, Nesheim ME, Mann KG. The factor Xa catalyzed activation of factor V. J Biol Chem 1983;258: 13970-13977.
13. Kane WH, Lindhout MJ, Jackson CM, Majerus PW. Factor Va dependent binding of factor Xa to human platelets. J Biol Chem 1980;255:1170-1174.
14. Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on human platelets. J Biol Chem 1978;253:6908-6916.
15. Miletich JP, Majerus DW, Majerus PW. Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets. J Clin Invest 1978;62:824-831.
16. Mann KG, Nesheim ME, Church WR, Huley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K dependent enzyme complexes. Blood 1990;76:1-16.
17. Hatton MWC, Moar SL, Richardson M. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface. Am J Pathol 1989;135:499-508.
18. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-1569.
19. Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the action of interleukin-1. Proc Natl Acad Sci USA 1986;83:4533-4537.
20. Nawroth PP, Handley DA, Esmon CT, et al. Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc Natl Acad Sci USA 1986;83:3460-3464.
21. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: Insight gained from studies using markers of hemostatic system activation. Blood 1987;70:343-350.
22. Nossel HL, Yudelman I, Canfield RE, et al. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974;54: 43-53.
23. Nossel HL, Ti M, Kaplan KL, Spanondis K, Soland T, Butler VP Jr. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976;58:1136-1144.
24. Kockum C, Frebelius S. Rapid radioimmunoassay of human fibrinopeptide A: Removal of cross reacting fibrinogen with bentonite. Thromb Res 1980;19:589-598.
25. Miller GJ, Bauer KA, Barzegar S, et al. The effect of quality and timing of veni puncture on markers of blood coagulation in healthy middle-aged men. Thromb Hemost 1995;73:82-86.
26. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/prothrombin fragment 1+2 fragment and thrombin/antithrombin complex. Blood 1982;59:1086-1097.
27. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991;65:153-159.
28. Bauer KA, Kass BL, Beeler DL, Rosenberg RD. Detection of protein C activation in humans. J Clin Invest 1984;74: 2033-2041.
29. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973;248:6590-6505.
30. Sherman MA, Pizzo SV. The in vivo metabolism of antithrombin III and antithrombin III complex. J Biol Chem 1983;257:3243-3248.
31. Lau HK, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the thrombin-antithrombin complex. J Biol Chem 1980;255:5885-5893.
32. Peltzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin-III-complex in plasma with an enzyme-linked immunosorbent assay. Thromb Hemost 1988;59:101-106.
33. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: A marker of acute coronary thrombosis. Circulation 1985;71:912-918.
34. Gulba DC, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Circulation 1991;83:937-944.
35. Eisenberg PR, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986;7:1255-1262.
36. Gulba DC, Daniel WG, Simon R, et al. Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1990;16:563-568.
37. Eisenberg PR, Abendschein DR, Becker RC, Loscalzo J, Sobel BE, and the TIMI Investigators. Lack of suppression of thrombin activity in vivo: A determination of failure of recanalization (abstr). J Am Coll Cardiol 1993;21(Suppl. A):464A.
38. Haider AW, Andreotti F, Thompson GR, Kluft C, Maseri A, Davies GJ. Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction. Circulation 1996;94:2072-2076.
39. Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996;94:2064-2071.
40. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis: A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992;85:1699-1705.
41. Ouyang P, Shapiro EP, Gottlieb SO. Thrombolysis in post-infarction angina. Am J Cardiol 1991;68:124B-199B.
42. Shapiro EP, Brinker JA, Gottlieb SO, Guzman PA, Bulkley BH. Intracoronary thrombolysis 3 to 13 days after acute myocardial infarction for postinfarction angina pectoris. Am J Cardiol 1985;5:1453-1458.
43. Nakagawa S, Hanada Y, Koiwaya Y, Tanaka K. Angiographic features in the infarct-related artery after intracoronary urokinase followed by prolonged anticoagulation. Circulation 1988;78:1335-1344.
44. Serruys PW, Arnold AER, Brower RW, et al. Effects of continued rtPA administration in acute myocardial infarction - A quantitative coronary angiography study of a randomized trial. Eur Heart J 1987;8:1172-1181.
45. Gash AK, Spann JF, Sherry S, et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986;61:381-384.
46. GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782.
47. van Den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina complex coronary lesion morphology. Circulation 1989;79: 116-124.
48. Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated blood. Thromb Res 1989;55: 635-643.
49. Griffin JT, Cochran LHG. Recent advances in the understanding of contact activation reactions. Semin Thromb Hemost 1979;5:254-273.
50. Haskel DJ, Torr SR, Day KC, et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991;84: 821-827.
51. Liu L, Zhang Q, Spencer F, Michelson A, Gore J, Becker R. Persistent survival of platelet factor Va activity in plasma. Blood 1996;88:526a.
52. Greenberg JP, Packham MA, Guccione MA. The effect of pretreatment of human or rabbit platelets with chymotrypsin on their response to human fibrinogen and aggregating agents. Blood 1979;54:753-765.
53. Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 1988;77:660-668.
54. Selike FW, Wuillen JE, Brooks LA, Harrison DG. Endothelial modulation of the coronary vasculature in vessels perfused via mature collaterals. Circulation 1990;81:1938-1947.
55. Perason PJ, Scharff HV, Vanhoutte PM. Long term impairment of endothelial dependent relaxations to aggregating platelets after reperfusion injury in canine coronary arteries. Circulation 1990;81:1921-1926.
56. Kloner RA, Fiacommelli F, Alker KJ, Hale SL, Mathews R, Bellows S. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion. Circulation 1991;84:1958-1972.
57. Przyklenk K. Lethal myocardial reperfusion injury. J Thromb Thromboly 1997;4:5-153.
58. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.
59. Scharfstein JS, Abendschein DR, Eisenberg PR, et al. for the TIMI-5 Investigators. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. Am J Cardiol 1996;78:503-510.
60. Cannon CP, Becker RC, Loscalzo J, et al. Usefulness of APTT to predict bleeding for hirudin (and heparin) (abstr.) Circulation 1994;90:I563.
61. Becker R, Cannon C, George D, et al. Toward establishing anticoagulation guidelines for intravenous heparin administration among patients with myocardial infarction given tissue plasminogen activator (abstr.) J Am Coll Cardiol 1995;25(Suppl A):309A.
62. Becker R, Hebert J, Hurley T, Ma Y, Cannon CP. Early aPTT measurements are not a marker of in vivo thrombin inhibition among patients receiving thrombolytic therapy and adjunctive anticoagulation. J Am Coll Cardiol 1996;27(Suppl. A):11A.
63. Lee LV, for the TIMI 6 Investigators. Initial experience with hirudin and streptokinase in acute myocardial infarctions: Results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 1995;75:7-13.
64. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90:1624-1630.
65. TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 1996;94:911-921.
66. The TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993;87:38-52.
67. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial. Circulation 1994;89:1545-1556.
68. Becker RC, Cannon CP, Tracy RP, et al. for the Thrombolysis in Myocardial Ischemia IIIB Investigators. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction. Am Heart J 1996;131: 421-433.
69. Becker RC, Tracy RP, Bovill EG, Corrao JM, Baker S, Ball SP, Mann KG, for the TIMI III Thrombosis and Coagulation Study Group. Surface 12-lead electrocardiographic findings and plasma markers of thrombin activity and generation in patients with myocardial ischemia at rest. J Thromb Thrombolys 1994;1:101-107.
70. Becker RC, Bovill EG, Corrao JM, Ball SP, Ault K, Mann K, Tracy RP, for the TIMI III Thrombosis and Coagulation Study Group. Platelet activation determined by flow cytometry persists despite antithrombotic therapy in patients with unstable angina and non-Q-wave myocardial infarction. J Thromb Thrombolysis 1994;1:95-100.
71. Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990;64:464-468.
72. Zoldhelyi P, Bichler J, Owen WG, et al. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994;90:2671-2678.
73. Rao AK, Sun L, Chesebro JH, et al. for the Hirudin in Unstable Angina Trial. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A Multicenter Trial. Circulation 1996;94:2389-2395.